Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology

Open access

Abstract

The limited understanding of the heterogeneity in the treatment response to antidiabetic drugs contributes to metabolic deterioration and cardiovascular complications 1,2, stressing the need for more personalized treatment 1. Although recent attempts have been made to classify diabetes into subgroups, the utility of such stratification in predicting treatment response is unknown 3. We enrolled participants with type 2 diabetes (n = 239, 74 women and 165 men) and features of severe insulin-deficient diabetes (SIDD) or severe insulin-resistant diabetes (SIRD). Participants were randomly assigned to treatment with the glucagon-like peptide 1 receptor agonist semaglutide or the sodium–glucose cotransporter 2 inhibitor dapagliflozin for 6 months (open label). The primary endpoint was the change in glycated haemoglobin (HbA1c). Semaglutide induced a larger reduction in HbA1c levels than dapagliflozin (mean difference, 8.2 mmol mol−1; 95% confidence interval, −10.0 to −6.3 mmol mol−1), with a pronounced effect in those with SIDD. No difference in adverse events was observed between participants with SIDD and those with SIRD. Analysis of secondary endpoints showed greater reductions in fasting and postprandial glucose concentrations in response to semaglutide in participants with SIDD than in those with SIRD and a more pronounced effect on postprandial glucose by dapagliflozin in participants with SIDD than in those with SIRD. However, no significant interaction was found between drug assignment and the SIDD or SIRD subgroup. In contrast, continuous measures of body mass index, blood pressure, insulin secretion and insulin resistance were useful in identifying those likely to have the largest improvements in glycaemic control and cardiovascular risk factors by adding semaglutide or dapagliflozin. Thus, systematic evaluation of continuous pathophysiological variables can guide the prediction of the treatment response to these drugs and provide more information than stratified subgroups (NCT04451837).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s42255-023-00943-3

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Study profile shown as a CONSORT diagram. Participants with at least one value after randomization were included in the full analysis set. The most common reason for study discontinuation was the occurrence of side effects from any of the drugs. Two participants inadvertently changed the metformin dose during the study; one participant underwent surgery for coronary artery bypass graft; one participant underwent gastric sleeve surgery; one participant stopped the study medication because of a misunderstanding; and one participant was lost to follow-up. Source data
Fig. 1 Study profile shown as a CONSORT diagram. Participants with at least one value after randomization were included in the full analysis set. The most common reason for study discontinuation was the occurrence of side effects from any of the drugs. Two participants inadvertently changed the metformin dose during the study; one participant underwent surgery for coronary artery bypass graft; one participant underwent gastric sleeve surgery; one participant stopped the study medication because of a misunderstanding; and one participant was lost to follow-up. Source dataCC BY · PubMed Central
Fig. 2 Changes over time in fasting and postprandial measures. Data show means and s.d. of fasting and postprandial measures in response to each study drug in participants with SIDD and SIRD. Measurements were obtained at baseline (0) and after 6 months of treatment (HbA1c was also measured at 3 months). Statistics for comparisons of the primary and secondary variables are presented in Table 2 and Supplementary Table 4. Average glucose measures were obtained from continuous glucose monitoring. Glucose and insulin excursions at 0, 30, 60, 90 and 120 min of the OGTT at baseline (0 months) and after 6 months are also shown, as well as the disposition index and insulin sensitivity index derived from the OGTT. Data represent n = 57 for dapagliflozin treatment in the SIDD group (16 women, 41 men), indicated by blue lines; n = 47 for dapagliflozin treatment in the SIRD group (14 women, 33 men), indicated by orange lines; n = 49 for semaglutide treatment in the SIDD group (14 women, 35 men), indicated by grey lines; and n = 44 for semaglutide treatment in the SIRD group (16 women, 28 men), indicated by yellow lines. Numbers include participants who underwent blood sampling at both baseline and 6 months. The last semaglutide dose was administered 3 days before the final OGTT and the last dapagliflozin dose was administered 12 h before the final OGTT to provide an average steady-state condition for both drugs with regard to their different half-lives. Source data
Fig. 2 Changes over time in fasting and postprandial measures. Data show means and s.d. of fasting and postprandial measures in response to each study drug in participants with SIDD and SIRD. Measurements were obtained at baseline (0) and after 6 months of treatment (HbA1c was also measured at 3 months). Statistics for comparisons of the primary and secondary variables are presented in Table 2 and Supplementary Table 4. Average glucose measures were obtained from continuous glucose monitoring. Glucose and insulin excursions at 0, 30, 60, 90 and 120 min of the OGTT at baseline (0 months) and after 6 months are also shown, as well as the disposition index and insulin sensitivity index derived from the OGTT. Data represent n = 57 for dapagliflozin treatment in the SIDD group (16 women, 41 men), indicated by blue lines; n = 47 for dapagliflozin treatment in the SIRD group (14 women, 33 men), indicated by orange lines; n = 49 for semaglutide treatment in the SIDD group (14 women, 35 men), indicated by grey lines; and n = 44 for semaglutide treatment in the SIRD group (16 women, 28 men), indicated by yellow lines. Numbers include participants who underwent blood sampling at both baseline and 6 months. The last semaglutide dose was administered 3 days before the final OGTT and the last dapagliflozin dose was administered 12 h before the final OGTT to provide an average steady-state condition for both drugs with regard to their different half-lives. Source dataCC BY · PubMed Central
Extended Data Fig. 1 Design of study. Figure depicts the different study visits and allocation of randomized treatment. Source data
Extended Data Fig. 1 Design of study. Figure depicts the different study visits and allocation of randomized treatment. Source dataCC BY · PubMed Central
Extended Data Fig. 2 Changes over time of estimated glomerular filtration rate and liver parameters. Data show means and SD of estimated glomerular filtration rate (eGFR), alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), alkaline phosphatase (ALP), bilirubin and NAFLD liver fat score in response to each study drug in SIDD and SIRD participants, respectively, obtained at baseline (0) and after 6 months of treatment (eGFR was also measured at 3 months). Data represent n = 57 dapagliflozin in SIDD [16 women, 41 men]; n = 47 dapagliflozin in SIRD [14 women, 33 men]; n = 49 semaglutide in SIDD [14 women, 35 men]; n = 44 semaglutide in SIRD [16 women, 28 men]; numbers include participants who underwent blood sampling both at baseline and at 6 months. Source data
Extended Data Fig. 2 Changes over time of estimated glomerular filtration rate and liver parameters. Data show means and SD of estimated glomerular filtration rate (eGFR), alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), alkaline phosphatase (ALP), bilirubin and NAFLD liver fat score in response to each study drug in SIDD and SIRD participants, respectively, obtained at baseline (0) and after 6 months of treatment (eGFR was also measured at 3 months). Data represent n = 57 dapagliflozin in SIDD [16 women, 41 men]; n = 47 dapagliflozin in SIRD [14 women, 33 men]; n = 49 semaglutide in SIDD [14 women, 35 men]; n = 44 semaglutide in SIRD [16 women, 28 men]; numbers include participants who underwent blood sampling both at baseline and at 6 months. Source dataCC BY · PubMed Central
Extended Data Fig. 3 Relative importance of continuous baseline variables in predicting the change in HbA1c. Panels A and B show the relative importance of baseline variables (features) in predicting the change in HbA1c after treatment with dapagliflozin (n = 113 [31 women, 82 men]; panel A) or semaglutide (n = 107 [36 women, 71 men]; panel B). The full analysis set was included in these analyses, independent of SIDD or SIRD cluster, to investigate the continuous baseline variables across all individuals. The measures of relative feature importance sum up to 1 and were generated by XGBoost. The XGBoost algorithm per se is not intended to be used in routine clinical work but was employed here to identify continuous baseline variables that predict the change in HbA1c and which can easily be evaluated by clinicians to provide a better overall assessment of the likely treatment response (such that for example a patient with high BMI or low insulin secretion will likely have a more pronounced response to a particular drug) in conjunction with other clinical data and the general patient context. Blue bars indicate greater reduction in HbA1c with higher values of the baseline trait; red indicates greater reduction in HbA1c with lower values of the baseline trait (lower BMI is for example associated with greater improvement of HbA1c in response to dapagliflozin). Blue indication for the sex term implies greater reduction in women and red indicates greater reduction in men. BMI is body mass index; SBP systolic blood pressure; DBP diastolic blood pressure; eGFR estimated glomerular filtration rate; DI disposition index; ISI insulin sensitivity index; glucose at 120 min refers to glucose measured at 120 minutes. Time in range (the fraction of time with glucose between 3.9 and 10.0 mmol/l) and CV glucose (coefficient of variance of glucose) were obtained from continuous glucose monitoring during two weeks prior to treatment allocation. Source data
Extended Data Fig. 3 Relative importance of continuous baseline variables in predicting the change in HbA1c. Panels A and B show the relative importance of baseline variables (features) in predicting the change in HbA1c after treatment with dapagliflozin (n = 113 [31 women, 82 men]; panel A) or semaglutide (n = 107 [36 women, 71 men]; panel B). The full analysis set was included in these analyses, independent of SIDD or SIRD cluster, to investigate the continuous baseline variables across all individuals. The measures of relative feature importance sum up to 1 and were generated by XGBoost. The XGBoost algorithm per se is not intended to be used in routine clinical work but was employed here to identify continuous baseline variables that predict the change in HbA1c and which can easily be evaluated by clinicians to provide a better overall assessment of the likely treatment response (such that for example a patient with high BMI or low insulin secretion will likely have a more pronounced response to a particular drug) in conjunction with other clinical data and the general patient context. Blue bars indicate greater reduction in HbA1c with higher values of the baseline trait; red indicates greater reduction in HbA1c with lower values of the baseline trait (lower BMI is for example associated with greater improvement of HbA1c in response to dapagliflozin). Blue indication for the sex term implies greater reduction in women and red indicates greater reduction in men. BMI is body mass index; SBP systolic blood pressure; DBP diastolic blood pressure; eGFR estimated glomerular filtration rate; DI disposition index; ISI insulin sensitivity index; glucose at 120 min refers to glucose measured at 120 minutes. Time in range (the fraction of time with glucose between 3.9 and 10.0 mmol/l) and CV glucose (coefficient of variance of glucose) were obtained from continuous glucose monitoring during two weeks prior to treatment allocation. Source dataCC BY · PubMed Central
Extended Data Fig. 4 SHAP summary plots for the impact of baseline variables in predicting the change in HbA1c in response to dapagliflozin (upper panel) or semaglutide (lower panel). Each point in the figure corresponds to a participant, and the SHAP value reflects the impact of the baseline variable in predicting the change in HbA1c for that individual. For example, in the row corresponding to HbA1c in the upper panel, all individuals receiving dapagliflozin are plotted in accordance with how much baseline HbA1c predicts the change in HbA1c, and similar for BMI, SBP etc. Thus, for some participants, HbA1c may be a strong predictor and BMI less important, while for other individuals BMI may be the most important predictor. The variables are therefore arranged based on the mean of the absolute SHAP values for each variable. Upper panel shows data for dapagliflozin (n = 113 [31 women, 82 men]) and lower panel shows semaglutide (n = 107 [36 women, 71 men]). SBP denotes systolic blood pressure, DBP diastolic blood pressure, DI disposition index, ISI insulin sensitivity index, and CV glucose denotes coefficient of variation of glucose during continuous monitoring. Source data
Extended Data Fig. 4 SHAP summary plots for the impact of baseline variables in predicting the change in HbA1c in response to dapagliflozin (upper panel) or semaglutide (lower panel). Each point in the figure corresponds to a participant, and the SHAP value reflects the impact of the baseline variable in predicting the change in HbA1c for that individual. For example, in the row corresponding to HbA1c in the upper panel, all individuals receiving dapagliflozin are plotted in accordance with how much baseline HbA1c predicts the change in HbA1c, and similar for BMI, SBP etc. Thus, for some participants, HbA1c may be a strong predictor and BMI less important, while for other individuals BMI may be the most important predictor. The variables are therefore arranged based on the mean of the absolute SHAP values for each variable. Upper panel shows data for dapagliflozin (n = 113 [31 women, 82 men]) and lower panel shows semaglutide (n = 107 [36 women, 71 men]). SBP denotes systolic blood pressure, DBP diastolic blood pressure, DI disposition index, ISI insulin sensitivity index, and CV glucose denotes coefficient of variation of glucose during continuous monitoring. Source dataCC BY · PubMed Central
Extended Data Fig. 5 Variables predicting the change in BMI in response to semaglutide. The upper panel shows the relative importance of baseline variables (features) in predicting the change in BMI after treatment with semaglutide (n = 107). The measures of relative feature sum up to 1. All participants receiving semaglutide were included in these analyses, independent of SIDD or SIRD cluster, to investigate the continuous baseline variables across all individuals. Blue bars indicate greater reduction in BMI with higher values of the baseline trait; red indicates greater reduction in BMI with lower values of the baseline trait. Blue indication for the sex term implies greater reduction in women; red indicates greater reduction in men. The lower panel shows the SHAP summary plot for the impact of baseline variables in predicting the change in BMI in response to semaglutide. The upper panel is arranged according to the relative importance of the variable predicting the outcome across all individuals, that is denotes how important a variable is on average in predicting the treatment response across all participants. The lower panel is arranged based on the mean of the absolute SHAP values for each variable, where individual values with large impact in a specific participant can influence the mean for that particular variable, while the variable across all participants may be of less relative importance. BMI is body mass index; SBP systolic blood pressure; DBP diastolic blood pressure; eGFR estimated glomerular filtration rate; DI disposition index; ISI insulin sensitivity index; Glucose at 120 min refers to glucose measured at 120 minutes. Time in range (the fraction of time with glucose between 3.9 and 10.0 mmol/l) and CV glucose (coefficient of variance of glucose) were obtained from continuous glucose monitoring during two weeks prior to treatment allocation. Source data
Extended Data Fig. 5 Variables predicting the change in BMI in response to semaglutide. The upper panel shows the relative importance of baseline variables (features) in predicting the change in BMI after treatment with semaglutide (n = 107). The measures of relative feature sum up to 1. All participants receiving semaglutide were included in these analyses, independent of SIDD or SIRD cluster, to investigate the continuous baseline variables across all individuals. Blue bars indicate greater reduction in BMI with higher values of the baseline trait; red indicates greater reduction in BMI with lower values of the baseline trait. Blue indication for the sex term implies greater reduction in women; red indicates greater reduction in men. The lower panel shows the SHAP summary plot for the impact of baseline variables in predicting the change in BMI in response to semaglutide. The upper panel is arranged according to the relative importance of the variable predicting the outcome across all individuals, that is denotes how important a variable is on average in predicting the treatment response across all participants. The lower panel is arranged based on the mean of the absolute SHAP values for each variable, where individual values with large impact in a specific participant can influence the mean for that particular variable, while the variable across all participants may be of less relative importance. BMI is body mass index; SBP systolic blood pressure; DBP diastolic blood pressure; eGFR estimated glomerular filtration rate; DI disposition index; ISI insulin sensitivity index; Glucose at 120 min refers to glucose measured at 120 minutes. Time in range (the fraction of time with glucose between 3.9 and 10.0 mmol/l) and CV glucose (coefficient of variance of glucose) were obtained from continuous glucose monitoring during two weeks prior to treatment allocation. Source dataCC BY · PubMed Central
Extended Data Fig. 6 Variables predicting the change in BMI in response to dapagliflozin. The panels are arranged and bars indicated in blue or red as described for Extended Data Fig. 5 (n = 113). Source data
Extended Data Fig. 6 Variables predicting the change in BMI in response to dapagliflozin. The panels are arranged and bars indicated in blue or red as described for Extended Data Fig. 5 (n = 113). Source dataCC BY · PubMed Central
Extended Data Fig. 7 Variables predicting the change in systolic blood pressure in response to semaglutide. The panels are arranged and bars indicated in blue or red as described for Extended Data Fig. 5 (n = 107). Source data
Extended Data Fig. 7 Variables predicting the change in systolic blood pressure in response to semaglutide. The panels are arranged and bars indicated in blue or red as described for Extended Data Fig. 5 (n = 107). Source dataCC BY · PubMed Central
Extended Data Fig. 8 Variables predicting the change in systolic blood pressure in response to dapagliflozin. The panels are arranged and bars indicated in blue or red as described for Extended Data Fig. 5 (n = 113). Source data
Extended Data Fig. 8 Variables predicting the change in systolic blood pressure in response to dapagliflozin. The panels are arranged and bars indicated in blue or red as described for Extended Data Fig. 5 (n = 113). Source dataCC BY · PubMed Central
Extended Data Fig. 9 Variables predicting the combined change in HbA1c, BMI and systolic blood pressure in response to semaglutide. The panels are arranged as described for Extended Data Fig. 5 (n = 107). Source data
Extended Data Fig. 9 Variables predicting the combined change in HbA1c, BMI and systolic blood pressure in response to semaglutide. The panels are arranged as described for Extended Data Fig. 5 (n = 107). Source dataCC BY · PubMed Central
Extended Data Fig. 10 Variables predicting the combined change in HbA1c, BMI and systolic blood pressure in response to dapagliflozin. The panels are arranged as described for Extended Data Fig. 5 (n = 113). Source data
Extended Data Fig. 10 Variables predicting the combined change in HbA1c, BMI and systolic blood pressure in response to dapagliflozin. The panels are arranged as described for Extended Data Fig. 5 (n = 113). Source dataCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 43

Metadata

Authors
Dwibedi, C., Ekström, O., Brandt, J., Adiels, M., Franzén, S., Abrahamsson, B., & Rosengren, A. H.
Affiliations
  • University of Gothenburg (SE)
  • Lund University (SE)
  • Skåne University Hospital (SE)
  • AstraZeneca (Sweden) (SE)
Corresponding author
Rosengren, Anders H.
Venue
Nature Metabolism
Published
2024-01-04
Volume
6
Issue
1
Pages
50-60
ISSN
2522-5812 (ISSN-L)
OpenAlex
W4390581855
Cited by
40
References
36
Citations by year
2026: 11 · 2025: 19 · 2024: 10
FWCI
13.17
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Metabolism (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • KTH Publication Database DiVA (KTH Royal Institute of Technology) (submittedVersion, other-oa)
  • Lund University Publications (Lund University) (submittedVersion)
Funders
  • European Commission (HORIZON2020)
  • Lunds Universitet (2018–05973)
  • Knut och Alice Wallenbergs Stiftelse (2018-05973)
  • Vetenskapsrådet (05973, grant agreement no. 2018-05973, 2022-01301, 2018-, 201805973, No. 2018-05973)
  • Göteborgs Universitet
  • Uppsala Multidisciplinary Center for Advanced Computational Science
  • H2020 European Research Council (866510)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
type 2 diabetes, semaglutide, dapagliflozin, GLP-1 receptor agonists, SGLT2 inhibitors, severe insulin-deficient diabetes, severe insulin-resistant diabetes, HbA1c, glycemic control, postprandial blood glucose, insulin secretion, insulin resistance, body mass index, blood pressure, cardiovascular risk factors, treatment response prediction, personalized treatment
MeSH terms
Semaglutide, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Female, Glucose, Glucosides, Glycated Hemoglobin, Humans, Insulin, Insulin Resistance, Male, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology. https://app.cochat.ai/papers/10.1038/s42255-023-00943-3
The paper
Dwibedi, C., Ekström, O., Brandt, J., Adiels, M., Franzén, S., Abrahamsson, B., & Rosengren, A. H. (2024). Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology. Nature Metabolism. https://doi.org/10.1038/s42255-023-00943-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.